Argel Aguilar-Valles

Argel Aguilar-Valles

Auto-generated profile, based on publicly available information

Argel Aguilar-Valles

Department of Neuroscience, Carleton University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RYRafael Yuste
Rafael Yuste
MHMichael Hawrylycz
Michael Hawrylycz
NANadia Aalling
Nadia Aalling
AAArgel Aguilar-Valles
Argel Aguilar-Valles
DADetlev Arendt
Detlev Arendt
ELEd Lein
Ed Lein
To understand the function of cortical circuits, it is necessary to catalog their cellular diversity. Past attempts to do so using anatomical, physiological or molecular features of cortical cells have not resulted in a unified taxonomy of neuronal or glial cell types, partly due to limited data. Single-cell transcriptomics is enabling, for the first time, systematic high-throughput measurements of cortical cells and generation of datasets that hold the promise of being complete, accurate and permanent. Statistical analyses of these data reveal clusters that often correspond to cell types previously defined by morphological or physiological criteria and that appear conserved across cortical areas and species. To capitalize on these new methods, we propose the adoption of a transcriptome-based taxonomy of cell types for mammalian neocortex. This classification should be hierarchical and use a standardized nomenclature. It should be based on a probabilistic definition of a cell type and incorporate data from different approaches, developmental stages and species. A community-based classification and data aggregation model, such as a knowledge graph, could provide a common foundation for the study of cortical circuits. This community-based classification, nomenclature and data aggregation could serve as an example for cell type atlases in other parts of the body.

30 November 2020 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DGDanilo De Gregorio
Danilo De Gregorio
AAArgel Aguilar-Valles
Argel Aguilar-Valles
KPKatrin H. Preller
Katrin H. Preller
BHBoris Dov Heifets
Boris Dov Heifets
MHMeghan Hibicke
Meghan Hibicke
GGGabriella Gobbi
Gabriella Gobbi
A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as their ability to modulate functional brain connectivity. Moreover, MDMA, a compound belonging to the family of entactogens, has been demonstrated to be useful to treat post-traumatic stress disorders. In this review, the pharmacology of hallucinogenic compounds is summarized by underscoring the differences between psychedelic and nonpsychedelic hallucinogens as well as entactogens, and their behavioral effects in both animals and humans are described. Together, these data substantiate the potentials of these compounds in treating mental diseases.

15 May 2017 in Nature Medicine
Verified
Journal Article
Closed access
IGIlse Gantois
Ilse Gantois
AKArkady Khoutorsky
Arkady Khoutorsky
JPJelena Popic
Jelena Popic
AAArgel Aguilar-Valles
Argel Aguilar-Valles
EFErika Freemantle
Erika Freemantle
NSNahum Sonenberg
Nahum Sonenberg

1 September 2015 in Neuropharmacology
Verified
Journal Article
Closed access
AAArgel Aguilar-Valles
Argel Aguilar-Valles
WIWataru Inoue
Wataru Inoue
CRChristoph Rummel
Christoph Rummel
GLGiamal N. Luheshi
Giamal N. Luheshi

6 March 2023 in Cell Reports
Verified
Journal Article
Open access
VLVern Lewis
Vern Lewis
EBEmma M. Bonniwell
Emma M. Bonniwell
JLJanelle K. Lanham
Janelle K. Lanham
AGAbdi Ghaffari
Abdi Ghaffari
HSHooshmand Sheshbaradaran
Hooshmand Sheshbaradaran
JMJohn D. McCorvy
John D. McCorvy
Hallucinations limit the widespread therapeutic use of psychedelics as rapid-acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at >33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT2A and does not induce the head-twitch response (HTR) in mice, supporting its classification as a non-hallucinogenic 5-HT2A partial agonist. Unlike LSD, 2-Br-LSD lacks 5-HT2B agonism, an effect linked to cardiac valvulopathy. Additionally, 2-Br-LSD produces weak 5-HT2A β-arrestin recruitment and internalization in vitro and does not induce tolerance in vivo after repeated administration. In cultured rat cortical neurons, 2-Br-LSD induces dendritogenesis and spinogenesis, and increases active coping behaviour in mice, an effect blocked by the 5-HT2A-selective antagonist volinaserin (M100,907). 2-Br-LSD also reverses the behavioral effects of chronic stress. Overall, 2-Br-LSD has an improved pharmacological profile compared to LSD and may have profound therapeutic value for mood disorders and other indications.

16 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
AAArgel Aguilar-Valles
Argel Aguilar-Valles
DGDanilo De Gregorio
Danilo De Gregorio
EMEdna Matta-Camacho
Edna Matta-Camacho
MEMohammad J. Eslamizade
Mohammad J. Eslamizade
AKAbdessattar Khlaifia
Abdessattar Khlaifia
NSNahum Sonenberg
Nahum Sonenberg